Clinical trials: RhA - Rheumatoid Arthritis
Periodontitis, Arthritis, Rheumatoid
Rheumatoid Arthritis and Treatment of Periodontitis: a Randomized Clinical Trial.
Periodontitis is an infectious disease defined by bacteria-mediated inflammation of the supporting tissues of the teeth that if left untreated may ultimately lead to the destruction of the attachment apparatus, culminating in…
- Trial name
- NCT05271890
- Testing
- Immediate non-surgical periodontal treatment and oral hygiene instructions
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Pisa
Rheumatoid Arthritis
Central Aspects of Pain in Rheumatoid Arthritis
This study seeks to measure the psychometric properties of a newly developed Central Aspects of Pain in Rheumatoid Arthritis (CAP-RA) questionnaire, and investigate the ability of this questionnaire to measure central mechanisms…
- Trial name
- CAP-RA (NCT04515589)
- Where
- United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Nottingham
Rheumatoid Arthritis
Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
This is a single-center, single-arm, prospective study on the efficacy and safety of Bortezomib in addition to standard therapy in patients with refractory rheumatoid arthritis.
- Trial name
- NCT05805891
- Testing
- bortezomib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese SLE Treatment And Research Group
Rheumatoid Arthritis, Interstitial Lung Disease
Treatment Outcome and Prognostic Factors for Rheumatoid Arthritis (RA) Patients With Interstitial Lung Disease (ILD)
The objectives of this single center, prospective, non-interventional cohort is to understand patient characteristics, general treatment patterns, effectiveness/safety of conventional disease modifying antirheumatic drug (DMARD)…
- Trial name
- NCT03099525
- Testing
- ILD
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Hanyang University
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Phase I Study of ICP-022 in Healthy Subjects
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and…
- Trial name
- NCT03189017
- Testing
- ICP-022
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Innocare Pharma Australia Pty Ltd
Degenerative Arthritis, Rheumatoid Arthritis
Zimmer Trabecular Metal Total Ankle PMCF
The primary objective of this study is to obtain implant survivorship and clinical outcome data for commercially available Zimmer Trabecular Metal Total Ankle implants used in primary or revision total ankle arthroplasty.
- Conditions
- Degenerative Arthritis, Rheumatoid Arthritis, Post Traumatic Arthritis
- Trial name
- NCT02038140
- Testing
- Zimmer Trabecular Metal Total Ankle System
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active…
- Trial name
- ACT-MOVE (NCT02046603)
- Testing
- Tocilizumab, DMARDs, Oral Corticosteroids
- Where
- 38 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis, Healthy Controls
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
Persons with rheumatoid arthritis (RA) suffer from increased disability and mortality, in part resulting from skeletal muscle impairments.
- Trial name
- MusculRA (NCT04226131)
- Testing
- Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Duke University
Rheumatoid Arthritis
Rheum@Home: RA Remote Patient Monitoring
The goal of this pragmatic multicentre clinical trial is to investigate whether telemonitoring with Rheum@Home leads to less outpatient visits, while maintaining tight disease control and high patient-experienced quality of care…
- Trial name
- R@H (NCT05725577)
- Testing
- care via the telemedicine system, Routine care
- Where
- Netherlands
- Sponsor
- Medisch Spectrum Twente
Osteoarthritis, Rheumatoid Arthritis
Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)
The primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID associated GI Ulcers to patients prescribed a NSAID.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- CONVOY (NCT01519375)
- Where
- 8 sites in Sweden
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis, Spondyloarthritis
Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.
Ultra-processed foods (UPF) represent one of the mainstays of today's diet. They are defined by the NOVA classification system. It was demonstrated that UPF consumption was associated with activity of inflammatory bowel diseases…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Osteoarthritis
- Trial name
- NUTRIRIC (NCT06776965)
- Testing
- Dietary Questionnaire, Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Hospices Civils de Lyon
Rheumatoid Arthritis
Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
1. To assess the baseline (i.e. RA therapy initiation) characteristics in a real-world setting across two moderate RA cohorts: a Test Group of patients newly exposed to etanercept (Enbrel) therapy and a Control Group of patients…
- Trial name
- NCT01557322
- Testing
- etanercept, methotrexate (MTX)
- Volunteers
- 1,754 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis
Comparison of lower dosage etoricoxib (60 mg daily) with aceclofenac (100 mg bid) for their efficacy and safety in the treatment of rheumatoid arthritis (RA).
- Trial name
- NCT04144101
- Testing
- Etoricoxib, Aceclofenac
- Volunteers
- 40 people
- Sponsor
- Chung Shan Medical University
Rheumatoid Arthritis
A Study of TJ003234 in Rheumatoid Arthritis Patients
Study Purpose and Design: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in…
- Trial name
- NCT04457856
- Testing
- TJ003234 injection
- Where
- 5 sites in China
- Volunteers
- 63 people
- Sponsor
- I-Mab Biopharma US Limited
SLE, Rheumatoid Arthritis
Role of DcR3 in T Cell Activation in SLE and RA
Decoy receptor 3 (DcR3), a new member of tumor necrosis factor receptor (TNFR) superfamily, is a decoy receptor for FasL and could inhibit FasL-induced apoptosis, has recently been shown to induce costimulation of T cells.
- Trial name
- NCT00275899
- Where
- Taiwan
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Rheumatoid Arthritis
TOLERA: Tolerance Enhancement in RA
Although anti-citrullinated protein antibodies (ACPA) including anti-CCP2 antibodies are known to promote inflammation and joint destruction in patients suffering from ACPA-positive rheumatoid arthritis, there are currently no…
- Trial name
- TOLERA (NCT04120831)
- Testing
- Abatacept Injection
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Rheumatoid Arthritis
Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis
Background: Rheumatoid arthritis (RA) is often treated with drugs known as tumor necrosis factor (TNF) inhibitors, that can help decrease joint pain and swelling and can even result in RA remission.
- Trial name
- STARA (NCT01793519)
- Testing
- Etanercept, Infliximab, Adalimumab
- Where
- 2 sites in United States
- Volunteers
- 290 people
- Sponsor
- Georgetown University
Rheumatoid Arthritis
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer.
- Trial name
- NCT01643928
- Testing
- Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA…
- Trial name
- NCT02996500
- Testing
- PF-06650833, Tofacitinib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 269 people
- Sponsor
- Pfizer
Osteoarthritis, Avascular Necrosis
Cormet Post-PMA Study: New Enrollment
The primary objective of this study is to evaluate the performance of the Cormet Hip Resurfacing implant system in the post-approval environment.
- Conditions
- Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis
- Trial name
- PASNew (NCT00722007)
- Testing
- Cormet Hip Resurfacing
- Where
- 6 sites in United States
- Volunteers
- 147 people
- Sponsor
- Corin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.